Proof of principle trials: EEG surrogate endpoints

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Pivotal studies for antiepileptic drugs (AEDs) often require prolonged administration to demonstrate efficacy.
• Electroencephalogram (EEG) surrogate endpoints can offer valuable early evidence of human efficacy, aiding decision-making.

Purpose of the Study:

• To evaluate the utility of EEG surrogate endpoints for assessing the acute efficacy of antiepileptic drugs (AEDs).
• To explore the use of standardized EEG recordings and photoparoxysmal responses (PPRs) as outcome measures for drug evaluation.

Main Methods:

• Studies involved standardized EEG recording conditions with tasks to maintain vigilance, measuring spike counts or discharge duration.
• Sub-acute experiments used ambulatory monitoring or telemetry.
• Photoparoxysmal responses (PPRs) in photosensitive subjects were evoked using standardized stimulation protocols to measure drug effects on photosensitivity.

Main Results:

• Acute EEG effects of AEDs were demonstrated through studies of spontaneous EEG discharges.
• Reduction in photosensitivity, indicated by a reduced range or abolition of PPRs, was observed after single doses of various AEDs.
• Neurotoxicity and sedative effects were assessed using evoked potentials, nerve conduction studies, and quantitative EEG analysis.

Conclusions:

• EEG surrogate endpoints, particularly PPR reduction, can provide meaningful early evidence of AED efficacy, even for drugs not typically used for long-term treatment of photosensitive epilepsy.
• These methods can accelerate decision-making in drug development and offer insights into acute drug effects and potential neurotoxicity.